Welcome to our dedicated page for Ashland news (Ticker: ASH), a resource for investors and traders seeking the latest updates and insights on Ashland stock.
Ashland Inc. (NYSE: ASH) is a premier global specialty chemicals company that serves a wide range of consumer and industrial markets. With a workforce of nearly 7,000 passionate professionals, including renowned scientists, research chemists, talented engineers, and plant operators, Ashland thrives on developing practical, innovative, and elegant solutions to complex problems for customers in more than 100 countries.
Operating in four distinct segments—Life Sciences, Personal Care, Specialty Additives, and Intermediates—Ashland is a key supplier to pharmaceutical companies, manufacturers of personal care products, food and beverages, nutraceuticals, and supplements. The Life Sciences segment generates the highest revenue, reflecting the company’s strong focus on this area.
Recently, Ashland announced significant organizational changes within its finance, strategy, mergers and acquisitions (M&A), and portfolio teams. The company has also issued its first-quarter financial results for fiscal year 2024 and outlined its outlook for the second quarter and full year. Ashland's leadership positions in high-quality, consumer-focused markets such as pharmaceuticals, personal care, and architectural coatings underline its commitment to excellence.
Ashland continues to foster gender equity and empowerment by spotlighting inspirational female employees, particularly in recognition of International Women’s Day. The company recently increased its support for greenlight4girls, a global initiative to inspire girls in STEM fields.
In line with its strategic goals, Ashland has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. The transaction, expected to close in the third quarter of 2024, is subject to customary closing conditions.
For the latest updates and more detailed information, visit the official Ashland website and the Investor Relations section.
Ashland (NYSE: ASH) announced the appointment of Alessandra Faccin as senior vice president and general manager of its Life Sciences division, effective June 10, 2024. Faccin brings over 20 years of experience in global industrial and manufacturing industries, having most recently served as president of Sealed Air , Asia Pacific. She has a broad financial background and has held leadership roles at Dow Chemical and Rohm & Haas. Faccin's educational background includes a Bachelor's in business administration from Fundação Getúlio Vargas and an Executive MBA from Universidade de São Paulo, along with certifications from The Wharton School and Villanova University.
Ashland Inc. (NYSE: ASH) appoints Ashish K. Kulkarni, CEO of Kebotix, to its Board of Directors. Kulkarni brings vast experience from leading companies, enhancing innovation, growth, and profitability. The Board expands to 11 members with his addition.
Ashland Inc. (ASH) board of directors has approved a quarterly dividend of $0.405 per share, marking a five percent increase from the prior quarter. The dividend will be paid on June 15, 2024, to stockholders on record as of June 1, 2024. As of April 30, 2024, there were 50,128,349 shares of Ashland common stock outstanding.
Turnspire Capital Partners has announced the acquisition of the nutraceuticals business of Ashland Inc. The acquisition includes Ashland Nutraceuticals, a leading provider of nutrition ingredients and custom formulation services for the nutrition market. Ashland Nutraceuticals has approximately 500 employees across four production facilities in the US and Mexico. The transaction is expected to be completed in the third quarter of 2024.
Ashland Inc. (NYSE: ASH) has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners The transaction is set to close in the third quarter of 2024. Ashland's nutraceuticals business offers active ingredients and formulation aids to nutritional product companies, alongside custom formulation and contract manufacturing services. The deal highlights the business's strong portfolio and capabilities.
Ashland Inc. (NYSE: ASH) reported financial results for the second quarter of fiscal year 2024, with sales at $575 million, down five percent from the prior-year quarter. Net income reached $120 million, or $2.39 per diluted share. Adjusted EBITDA was $126 million, and cash flows from operating activities were $54 million. The company's outlook for the third quarter and full-year fiscal 2024 shows an optimistic perspective on the demand normalization in key segments like Personal Care and Specialty Additives.
FAQ
What is the current stock price of Ashland (ASH)?
What is the market cap of Ashland (ASH)?
What does Ashland Inc. specialize in?
How many employees does Ashland Inc. have?
What are the main business segments of Ashland Inc.?
Who are some of Ashland Inc.'s key customers?
What recent organizational changes has Ashland Inc. announced?
How does Ashland Inc. support gender equity?
What strategic transaction did Ashland Inc. recently announce?
Where can I find Ashland Inc.'s financial updates?
What is Ashland Inc.'s ticker symbol and where is it listed?
What are some key markets served by Ashland Inc.?
